A selective estrogen receptor modulator, raloxifene, was suggested to be potentially effective for the treatment of psoriasis as an inhibitor of IL-12p40 and tumor necrosis factor (TNF)-α (36). The gene discussed is ESR1; the disease is psoriasis.